ResearcherHarvard UniversityActive in the last 2 years
Saurav Daniel Haldar
Matched on ORCID iD 0000-0002-2346-0566; OpenAlex author ID A5056139519. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 2, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 42
2018: 1 paper · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: 1 paper · 2025: none · 2026: 4 papers
Papers 6
- Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial. First author DOI 10.1038/s41467-026-68324-4↗
- Publisher Correction: Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial First author DOI 10.1038/s41467-026-71968-x↗
- Phase I trial of binimetinib plus hydroxychloroquine in patients with previously treated metastatic pancreatic cancer. Co-author DOI 10.1093/oncolo/oyag071↗
- First-in-human testing of a mutant KRAS vaccine for pancreatic cancer interception in high-risk cohorts. Co-author DOI 10.1158/2159-8290.cd-25-2245↗
- Unlocking the promise of RAS inhibition in pancreatic cancer. Co-author DOI 10.1038/s41575-024-00951-y↗
- Discovery and optimization of aspartate aminotransferase 1 inhibitors to target redox balance in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.bmcl.2018.04.061↗
Closest collaborators
The 25 strongest of 42 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Nilofer Saba Azad · 4 shared papers, 2024–2026 · strength 1.04
- Paper Unlocking the promise of RAS inhibition in pancreatic cancer. DOI 10.1038/s41575-024-00951-y↗
- Paper First-in-human testing of a mutant KRAS vaccine for pancreatic cancer interception in high-risk cohorts. DOI 10.1158/2159-8290.cd-25-2245↗
- Paper Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial. DOI 10.1038/s41467-026-68324-4↗
- Hao Wang · 3 shared papers, 2026 · strength 0.58
- Paper First-in-human testing of a mutant KRAS vaccine for pancreatic cancer interception in high-risk cohorts. DOI 10.1158/2159-8290.cd-25-2245↗
- Paper Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial. DOI 10.1038/s41467-026-68324-4↗
- Paper Publisher Correction: Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial DOI 10.1038/s41467-026-71968-x↗
- Marina Baretti · 3 shared papers, 2026 · strength 0.58
- Paper First-in-human testing of a mutant KRAS vaccine for pancreatic cancer interception in high-risk cohorts. DOI 10.1158/2159-8290.cd-25-2245↗
- Paper Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial. DOI 10.1038/s41467-026-68324-4↗
- Paper Publisher Correction: Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial DOI 10.1038/s41467-026-71968-x↗
- Luciane Tsukamoto Kagohara · 3 shared papers, 2026 · strength 0.58
- Paper First-in-human testing of a mutant KRAS vaccine for pancreatic cancer interception in high-risk cohorts. DOI 10.1158/2159-8290.cd-25-2245↗
- Paper Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial. DOI 10.1038/s41467-026-68324-4↗
- Paper Publisher Correction: Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial DOI 10.1038/s41467-026-71968-x↗
- Mark M. Yarchoan · 3 shared papers, 2026 · strength 0.58
- Paper First-in-human testing of a mutant KRAS vaccine for pancreatic cancer interception in high-risk cohorts. DOI 10.1158/2159-8290.cd-25-2245↗
- Paper Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial. DOI 10.1038/s41467-026-68324-4↗
- Paper Publisher Correction: Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial DOI 10.1038/s41467-026-71968-x↗
- Neeha Zaidi · 3 shared papers, 2026 · strength 0.58
- Paper First-in-human testing of a mutant KRAS vaccine for pancreatic cancer interception in high-risk cohorts. DOI 10.1158/2159-8290.cd-25-2245↗
- Paper Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial. DOI 10.1038/s41467-026-68324-4↗
- Paper Publisher Correction: Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial DOI 10.1038/s41467-026-71968-x↗
- Elizabeth M. Jaffee · 3 shared papers, 2026 · strength 0.58
- Paper First-in-human testing of a mutant KRAS vaccine for pancreatic cancer interception in high-risk cohorts. DOI 10.1158/2159-8290.cd-25-2245↗
- Paper Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial. DOI 10.1038/s41467-026-68324-4↗
- Paper Publisher Correction: Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial DOI 10.1038/s41467-026-71968-x↗
- Won Jin Ho · 3 shared papers, 2026 · strength 0.58
- Paper First-in-human testing of a mutant KRAS vaccine for pancreatic cancer interception in high-risk cohorts. DOI 10.1158/2159-8290.cd-25-2245↗
- Paper Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial. DOI 10.1038/s41467-026-68324-4↗
- Paper Publisher Correction: Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial DOI 10.1038/s41467-026-71968-x↗
- Katherine M. Bever · 3 shared papers, 2026 · strength 0.58
- Paper First-in-human testing of a mutant KRAS vaccine for pancreatic cancer interception in high-risk cohorts. DOI 10.1158/2159-8290.cd-25-2245↗
- Paper Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial. DOI 10.1038/s41467-026-68324-4↗
- Paper Publisher Correction: Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial DOI 10.1038/s41467-026-71968-x↗
- Amanda L. Huff · 3 shared papers, 2026 · strength 0.58
- Paper First-in-human testing of a mutant KRAS vaccine for pancreatic cancer interception in high-risk cohorts. DOI 10.1158/2159-8290.cd-25-2245↗
- Paper Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial. DOI 10.1038/s41467-026-68324-4↗
- Paper Publisher Correction: Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial DOI 10.1038/s41467-026-71968-x↗
- Daniel A. Laheru · 3 shared papers, 2026 · strength 0.58
- Paper First-in-human testing of a mutant KRAS vaccine for pancreatic cancer interception in high-risk cohorts. DOI 10.1158/2159-8290.cd-25-2245↗
- Paper Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial. DOI 10.1038/s41467-026-68324-4↗
- Paper Publisher Correction: Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial DOI 10.1038/s41467-026-71968-x↗
- Jae Woo Lee · 2 shared papers, 2026 · strength 0.38
- Robert A. Anders · 2 shared papers, 2026 · strength 0.38
- Elana Judith Fertig · 2 shared papers, 2026 · strength 0.38
- Janelle Marie Montagne · 2 shared papers, 2026 · strength 0.38
- Thatcher Ross Heumann · 2 shared papers, 2026 · strength 0.38
- Michael James Overman · 1 shared paper, 2026 · strength 0.23
- J. Jack LEE · 1 shared paper, 2026 · strength 0.23
- Dan Zhao · 1 shared paper, 2026 · strength 0.23
- Jason A. Willis · 1 shared paper, 2026 · strength 0.23
- Robert A. Wolff · 1 shared paper, 2026 · strength 0.23
- Rishi Surana · 1 shared paper, 2026 · strength 0.23
- Channing J. Der · 1 shared paper, 2026 · strength 0.23
- Anirban Maitra · 1 shared paper, 2026 · strength 0.23
- Brandon George Smaglo · 1 shared paper, 2026 · strength 0.23
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.